Blog

Nelson Advisors has been invited to mentor and judge the MedTech Innovator 2026 programme alongside a panel of esteemed US and European industry executives. &nbsp;&nbsp; Now in its 13th year, MedTech Innovator, the world’s largest medtech accelerator continues to identify the most promising medical device, diagnostic, and digital health startups developing innovative tools to improve patient care. Source: <a href="https://medtechinnovator.org">https://medtechinnovator.org</a>MedTech Innovator is the world's largest accelerator for medical device, digital health, and diagnostic companies. Our mission is to improve patients' lives by accelerating the growth of companies transforming healthcare worldwide. &nbsp;&nbsp; "According to Silicon Valley Bank’s CipherBio, MedTech Innovator is the largest accelerator of Life Science companies in the world. The dominant part of our portfolio is Medical Devices, in addition to our leadership position as an accelerator of diagnostics, digital health, and life science tools technologies. 93% of our portfolio are still in business or have been acquired, and 86% of our companies have raised equity financing. In Q1 2023, approximately 30% of all funds raised in the medtech sector went to a graduate of MedTech Innovator." &nbsp;&nbsp; Our corporate partners include leading manufacturers like Johnson &amp; Johnson, Dexcom, NIPRO Medical Corp., Olympus Medical Systems Group, W. L. Gore &amp; Associates, Asahi Intecc, Edwards Lifesciences, Fujikura, Jabil Healthcare, Maxim Integrated Ventures. and many others. They participate as thought leaders, application reviewers, event judges, and accelerator mentors. &nbsp;&nbsp; Hundreds of investors like RCT Ventures, Aphelion Capital, Life Science Angels, Healthtech Capital, Sofinnova Partners, Vensana, Treo, Hunniwell Lake Partners, Seroba Life Sciences participate as application reviewers, mentors, and judges. &nbsp;&nbsp; <a href="https://medtechinnovator.org/about-us/">https://medtechinnovator.org/about-us/</a>MedTech Innovator is the world’s largest accelerator of medical technology companies, with a mission to improve the lives of patients by accelerating the growth of transformative health care startups.&nbsp;Along with its sibling programs, BioTools Innovator and MedTech Innovator Asia Pacific, the organization provides founders with mentorship, exposure to industry leaders, and access to funding opportunities.&nbsp; Each year, thousands of startups compete for a place in the programs’ cohorts, gaining global visibility and connections that help bring their innovations to market faster.

Nelson Advisors invited to judge the MedTech Innovator 2026 Programme

Nelson Advisors Partner Lloyd Price asked to Judge the 'HealthInvestor Power List Awards' recognising the most effective, inspiring and influential leaders in Health and Social Care.The HealthInvestor Power List celebrates effective, inspiring and influential figures in health and social care, including standout leaders, investors and advisors to the sector.Entries for the HealthInvestor Power List 2026 will open in May 2026.Nexus Media Group &nbsp;&nbsp; The Awards are hosted by Nexus Media Group, a leading B2B publishing and events company for the health, social care, seniors housing, education, early years and property sectors. &nbsp;&nbsp; Nexus Media Group is a publishing and events company, which focuses on the health, education, early-years and property sectors. Our range of established media titles and sector-leading events provide market intelligence and business connections, underpinned by a long-standing commitment to editorial excellence. &nbsp; Established in 2004, our London-based team of journalists and sector experts provide insight and introductions to complex marketplaces.Source: <a href="https://healthinvestorpowerlist.com/judges-2025/" data-mce-href="https://healthinvestorpowerlist.com/judges-2025/">https://healthinvestorpowerlist.com/judges-2025/</a>

Nelson Advisors joins expert judging panel for HealthInvestor Power List Awards

Since 2013, EquityZen has made it easy to buy and sell shares in the private companies &nbsp;aspiring to transform our world.EquityZen is a pioneer in democratizing private markets investing, offering convenient access to investment opportunities via our funds, and a proven track record of successful private placements across a wide range of companies.Abridge is a medical conversation AI startup that structures and summarizes medical conversations for doctors and patients.Abridge develops generative AI technology designed to automate clinical documentation by recording and summarizing medical conversations directly into Electronic Medical Records (EMRs). The company aims to reduce administrative burdens for healthcare providers, thereby allowing clinicians to focus primarily on patient care.Macroeconomic Headwinds and Market Consolidation: The healthcare AI sector is entering a projected "collapse of point solutions" in 2026. Health systems, facing tighter margins due to the One Big Beautiful Bill Act (OBBBA) and expiring ACA subsidies, are increasingly consolidating their tech stacks. This creates a "maturity wall" where Abridge must prove hard ROI rather than just "soft" metrics like time saved. Competitively, the risk of "platform capture" by EHR giants like Epic, who may eventually develop native, low-cost alternatives, remains a primary long-term threat to Abridge’s premium pricing model.Source: <a href="https://equityzen.com/company/abridged1a4/" data-mce-href="https://equityzen.com/company/abridged1a4/" data-mce-selected="inline-boundary">https://equityzen.com/company/abridged1a4/﻿</a>Reference:<a href="https://www.healthcare.digital/single-post/why-do-founders-and-investors-fear-an-ai-bubble-could-burst-in-healthcare-in-2026" data-mce-href="https://www.healthcare.digital/single-post/why-do-founders-and-investors-fear-an-ai-bubble-could-burst-in-healthcare-in-2026">https://www.healthcare.digital/single-post/why-do-founders-and-investors-fear-an-ai-bubble-could-burst-in-healthcare-in-2026</a>

Nelson Advisors referenced in EquityZen’s Abridge (ABRI) company and share analysis

Nelson Advisors referenced in Saudi British Joint Business Council and Arab British Chamber of Commerce Report.The year 2025 is a landmark for UK healthtech, with nearly half of all healthcare investment now channelled into AI-powered companies and digital solutions. In the first quarter, healthtech startups raised £1.35 billion, propelled by world-leading deals such as Isomorphic Labs’ £470 million funding round for AI-driven drug discovery4. The “Golden Triangle” of London, Oxford and Cambridge remains the crucible for healthtech research and innovation, but regional clusters, such as Manchester’s Science Park, demonstrate how infrastructure and local partnerships are furthering nationwide progress (5).The sector’s focus areas include AI-driven diagnostics, predictive analytics through digital twins and multiomic data, health data infrastructure, and increasingly, solutions aimed at personalised care and home-based health monitoring. Government investments, including a £600 million boost for health data research, are accelerating this transformation and securing the UK’s place at the frontier of global digital health innovation (6).5) <a href="https://nelsonadvisors.co.uk/blog/future-trends-for-uk-healthtech-investment">https://nelsonadvisors.co.uk/blog/future-trends-for-uk-healthtech-investment</a>6) <a href="https://nelsonadvisors.co.uk/blog/future-trends-for-uk-healthtech-investment">https://nelsonadvisors.co.uk/blog/future-trends-for-uk-healthtech-investment</a>Source: <a href="https://www.allurentis.com/_files/ugd/ff7369_e1366965c76745f8b5affe33d91be44a.pdf?index=true" data-mce-href="https://www.allurentis.com/_files/ugd/ff7369_e1366965c76745f8b5affe33d91be44a.pdf?index=true">https://www.allurentis.com/_files/ugd/ff7369_e1366965c76745f8b5affe33d91be44a.pdf?index=true</a>

Nelson Advisors referenced in Saudi British Joint Business Council and Arab British Chamber of Commerce Report

ViVE 2026 concluded on February 25th this week in Los Angeles, signalling a major shift in the industry, the "honeymoon phase" of experimental AI is over. The focus has moved from flashy pilots to operational accountability and measurable ROI.Here are 10 key observations and takeaways from the floor of ViVE 2026:1. The "Pilot to Platform" Pivot Executives agreed that the era of isolated AI pilots is closing. Health systems are now demanding enterprise-wide AI strategies that integrate directly into existing workflows. Investment is being funneled into tools that can scale across an entire organization rather than niche solutions that add to "app fatigue.2. Nursing Input is No Longer OptionalA major theme was the "Evolution of Nursing in a Tech-Enabled Future." Leaders emphasized that technology—especially ambient listening and AI documentation—often fails because it’s designed without bedside nurses at the table.The consensus: if a nurse didn't help build it, the frontline won't use it.3. Cybersecurity: From Prevention to Containment The narrative around cybersecurity has shifted from "keeping them out" to "limiting the blast radius." Radical moves were discussed, such as Baptist Health removing external email access for thousands of frontline staff to eliminate phishing risks—a strategy they call "Safe Mail."4. ROI is the New North Star With health systems facing thin margins, every digital tool must now prove its financial worth. Companies like Trinity Health shared roadmaps for eliminating nearly $80 million in operating expenses through tech-driven cost optimization, proving that digital health must now be a "margin protector."5. Interoperability as "Operational Transparency" Interoperability is moving beyond regulatory compliance (meeting CMS mandates) toward becoming a functional tool for clinical intelligence. The goal is no longer just "moving data," but ensuring that data provides a unified clinical view across imaging, pathology, and pharmacy in real time.6. The Rise of "Autonomous AI Agents" While 2025 was about "copilots," 2026 is the year of the Agent. Companies like Artera and HCLTech showcased autonomous AI agents capable of managing complex patient workflows, scheduling, FAQ resolution and intake, without human intervention, significantly reducing administrative burnout.7. Diagnostics at the Point of Care There was a heavy focus on moving high-level diagnostics out of specialized centers and into the community. Innovations in AI-enabled MRI interpretation and cardiology tools (like estimating heart function from limited imaging) are making specialty-level care accessible in local clinics.8. Direct-to-Employer Pharmacy Models GoodRx launched its "Employer Direct" platform at the show, reflecting a trend where employers are bypassing traditional pharmacy benefit frameworks to subsidize high-cost drugs (like GLP-1s) directly. This reflects a broader shift toward patient and employer agency in drug pricing.&nbsp;9. Patient-Led TransportationUber Health unveiled a new self-booking feature, allowing patients to book their own benefit-covered rides. Early pilots showed an 86% decrease in missed appointments, proving that giving patients autonomy—rather than relying on back-end provider booking—leads to better health outcomes.10. AI Governance as a Competitive Advantage As state and federal AI regulations tighten, organizations are positioning "AI Governance" as a business asset. Those who can prove their AI is transparent, unbiased, and safe are winning more contracts and patient trust than those who move fast and break things.Source: <a href="https://hlth.com/events/vive/" data-mce-href="https://hlth.com/events/vive/">https://hlth.com/events/vive/</a>

10 Key Observations from ViVE 2026

Across Europe this week you’re seeing three main HealthTech threads: stepped‑up public funding (notably Ireland’s new ARC Hub), continued tightening of the MDR/IVDR–AI Act regime and selective early‑stage capital going into neuro and infrastructure‑style digital health.Public funding and hubs Ireland formally launched the €34.3m ARC Hub for HealthTech, with RCSI and University of Galway as partner institutions, to back research‑led innovation and commercialisation in medtech and digital health. 2026 Horizon Europe “Health” calls went live this month, with topics including digital‑mental‑health harms in youth and long‑COVID, reinforcing EU‑level non‑dilutive capital for data‑ and AI‑heavy health projects.​ Regulation and policy The Commission’s late‑2025 MDR/IVDR “simplification” package is now the reference point in 2026, focusing on streamlined notified‑body oversight, clearer recertification timelines, and more explicit software and cybersecurity requirements for SaMD and connected medtech. EU AI Act high‑risk provisions for clinical AI are phasing in (full enforcement in March 2026), which is already steering capital toward explainable “glass‑box” models to satisfy transparency and human‑oversight standards. The new EU Health Technology Assessment Regulation (EU 2021/2282), applicable since January 2025, is bedding in: EMA and HTA bodies will run joint clinical assessments for certain high‑risk devices, impacting evidence packages and pan‑EU pricing/market access strategy.​ UK–EU device access In the UK, MHRA opened a consultation on routes to access medical devices approved in Europe, aiming to leverage EU approvals while maintaining domestic oversight, which matters for EU–UK launch sequencing and label strategy.​ Capital flows and startups Female‑led Danish startup Hemi Health raised c.€4m to scale migraine and concussion digital therapeutics internationally, emblematic of ongoing appetite for neuro and specialty‑care DTx despite a generally disciplined funding climate. Recent dealflow commentary still highlights capital concentration in regulated adjacencies such as AMR diagnostics, cardiology, and robotics, with rounds like ShanX Medtech’s ~€24m financing cited as representative of early‑2026 medtech funding focus.​ Sector‑wide analyses describe 2026 as a “great rationalisation” period: the end of venture‑subsidised experimentation and a stronger “flight to quality” toward assets with robust revenue, regulatory clarity and HTA‑ready data. Data, EHDS and infrastructure 2026 is being framed as a preparation year for the European Health Data Space, pushing HealthTech and medtech players to prioritise EHDS‑ready data architectures, anonymisation, governance and cross‑border data‑sharing for AI training and validation.​ EU‑level programmes are explicitly funding backend “plumbing” such as interoperability layers, real‑time monitoring platforms, remote surgical support, and hospital cybersecurity aligned with EHDS‑style data flows.To discuss how Nelson Advisors can help your HealthTech, MedTech, Health AI or Digital Health company, please email <a href="mailto:lloyd@nelsonadvisors.co.uk" data-mce-href="mailto:lloyd@nelsonadvisors.co.uk">lloyd@nelsonadvisors.co.uk</a>&gt;&gt;&gt;&gt;European MedTech this week is dominated by Brussels‑driven regulatory moves around MDR/IVDR and EUDAMED, plus UK steps to lean on CE‑marked devices, all against a backdrop of “industrial maturity” in funding and capital allocation.MDR/IVDR and notified bodies The Commission’s late‑2025 MDR/IVDR simplification proposals are shaping 2026 discussions, targeting streamlined notified‑body oversight, clearer recertification clocks (e.g. 60‑day review, 15‑day certificate issuance), and reduced admin burden while holding safety constant. A draft Implementing Act on Annex VII requirements for notified bodies aims to harmonise how NBs operate, with more uniform expectations and processes expected to ease capacity constraints and improve predictability for manufacturers. New harmonised standards under MDR/IVDR (end‑January decisions) now cover neurosurgical implants, biocompatibility, clinical investigations, sterilisation and labelling, tightening the technical baseline for a wide range of device categories.​ EUDAMED and 2026 deadlines Four key EUDAMED modules (actor registration, UDI/devices, notified bodies &amp; certificates, market surveillance) are now confirmed functional, starting a six‑month transition into mandatory use. From 28 May 2026, new MDR/IVDR devices must be in EUDAMED before EU market entry, with phased timelines for legacy MDD/AIMDD devices, driving manufacturers to accelerate data, UDI and PMS readiness this year. UK: CE‑mark recognition MHRA has launched a consultation (running to 10 April 2026) proposing indefinite recognition of CE‑marked devices in Great Britain, dropping earlier plans for a hard switch to standalone UKCA approvals.​ The proposal would align GB transitions with EU timelines, introduce an international reliance route for higher‑risk devices, and sit alongside new UK post‑market surveillance rules already in force.​ Capital flows and EU‑level funding Recent medtech dealflow commentary still points to capital concentration in AMR diagnostics, cardiology and robotics, with financings like ShanX Medtech’s c.€24m round used as reference cases for where early‑2026 money is going. EU‑level programmes (Horizon Europe, EIC STEP and medical‑technology‑specific calls) are actively funding multinational clinical studies for orphan and “breakthrough” devices, including AI‑enabled solutions, with typical grants in the €6–8m range per project and equity cheques of €10–30m for deep‑tech scale‑ups. Strategic framing: “industrial maturity” Strategic outlook pieces frame 2026 as a “great rationalisation” or industrial maturity phase for European MedTech: less appetite for speculative, pre‑evidence device plays and more emphasis on profitable efficiency, robust PMS and HTA‑ready clinical data. The AI Act’s 2026 high‑risk enforcement timeline is now a binary filter for device‑integrated AI: only teams with strong data governance, documentation and human‑oversight architectures are seen as bankable medtech targets.To discuss how Nelson Advisors can help your HealthTech, MedTech, Health AI or Digital Health company, please email <a href="mailto:lloyd@nelsonadvisors.co.uk" data-mce-href="mailto:lloyd@nelsonadvisors.co.uk">lloyd@nelsonadvisors.co.uk</a>

Nelson Advisors

Blog

Nelson Advisors invited to judge the MedTech Innovator 20...

Nelson Advisors joins expert judging panel for HealthInve...

Nelson Advisors referenced in EquityZen’s Abridge (ABRI) ...

Nelson Advisors referenced in Saudi British Joint Busines...

10 Key Observations from ViVE 2026

This Week in European MedTech and HealthTech: 27th Februa...